[go: up one dir, main page]

WO2022011332A3 - Immunogenic composition forming a vaccine, and a method for its manufacture - Google Patents

Immunogenic composition forming a vaccine, and a method for its manufacture Download PDF

Info

Publication number
WO2022011332A3
WO2022011332A3 PCT/US2021/041245 US2021041245W WO2022011332A3 WO 2022011332 A3 WO2022011332 A3 WO 2022011332A3 US 2021041245 W US2021041245 W US 2021041245W WO 2022011332 A3 WO2022011332 A3 WO 2022011332A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticle
immunogenic composition
composition forming
vaccine
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/041245
Other languages
French (fr)
Other versions
WO2022011332A2 (en
Inventor
Mitra Mosharraf
Aryo SORAYYA
Rajiv Nayar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engimata Inc
Original Assignee
Engimata Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/925,438 external-priority patent/US11278617B2/en
Priority claimed from US17/204,511 external-priority patent/US11559577B2/en
Application filed by Engimata Inc filed Critical Engimata Inc
Priority to EP21838378.4A priority Critical patent/EP4178545A4/en
Publication of WO2022011332A2 publication Critical patent/WO2022011332A2/en
Publication of WO2022011332A3 publication Critical patent/WO2022011332A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

An immunogenic composition forming a vaccine includes a nanoparticle adjuvant comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a spike protein from a coronavirus.
PCT/US2021/041245 2020-07-10 2021-07-12 Immunogenic composition forming a vaccine, and a method for its manufacture Ceased WO2022011332A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21838378.4A EP4178545A4 (en) 2020-07-10 2021-07-12 IMMUNOGENIC COMPOSITION FOR FORMING A VACCINE AND METHOD FOR THE PRODUCTION THEREOF

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/925,438 US11278617B2 (en) 2020-03-31 2020-07-10 Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture
US16/925,438 2020-07-10
US17/204,511 US11559577B2 (en) 2020-03-31 2021-03-17 Immunogenic composition forming a vaccine, and a method for its manufacture
US17/204,511 2021-03-17

Publications (2)

Publication Number Publication Date
WO2022011332A2 WO2022011332A2 (en) 2022-01-13
WO2022011332A3 true WO2022011332A3 (en) 2022-02-17

Family

ID=79553742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/041245 Ceased WO2022011332A2 (en) 2020-07-10 2021-07-12 Immunogenic composition forming a vaccine, and a method for its manufacture

Country Status (2)

Country Link
EP (1) EP4178545A4 (en)
WO (1) WO2022011332A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522249A (en) 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア coronavirus vaccine
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164181A1 (en) * 2006-12-29 2012-06-28 Pevion Biotech Ag Non-Specific Immunostimulating Agents
US20140341974A1 (en) * 2013-03-15 2014-11-20 Htd Biosystems Inc. Liposomal Vaccine Adjuvants and Methods of Making and Using Same
US20170258893A1 (en) * 2013-11-29 2017-09-14 The Trustees Of The University Of Pennsylvania MERS-CoV Vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191780A1 (en) * 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
AU2021233816A1 (en) * 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164181A1 (en) * 2006-12-29 2012-06-28 Pevion Biotech Ag Non-Specific Immunostimulating Agents
US20140341974A1 (en) * 2013-03-15 2014-11-20 Htd Biosystems Inc. Liposomal Vaccine Adjuvants and Methods of Making and Using Same
US20170258893A1 (en) * 2013-11-29 2017-09-14 The Trustees Of The University Of Pennsylvania MERS-CoV Vaccine

Also Published As

Publication number Publication date
EP4178545A2 (en) 2023-05-17
WO2022011332A2 (en) 2022-01-13
EP4178545A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
WO2022011332A3 (en) Immunogenic composition forming a vaccine, and a method for its manufacture
WO2022155530A8 (en) Variant strain-based coronavirus vaccines
WO2022120388A3 (en) Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
CN1096851C (en) Adjuvant for a vaccine composition
BR112013000244A2 (en) lipid liposomes having advantageous pka for administration of rna
MX2023005203A (en) Lipid nanoparticles for delivering mrna vaccines.
MX2009007087A (en) Methods of vaccine administration.
BRPI0410702A (en) isolated polynucleotide, composition, methods for preparing an influenza virus and a gene delivery vehicle, and for immunizing an individual against a pathogen, virus, cell, and, vector
EP4317177A4 (en) Novel coronavirus s-rbd trimeric protein vaccine, preparation method therefor, and application thereof
BRPI0000126B8 (en) vaccine composition, adjuvant composition and method of producing a vaccine composition
AR011216A1 (en) A VACCINE BASED ON SURFACE ANTIGENS AGAINST INFLUENZA, A METHOD FOR PREPARING IT, AND A METHOD FOR PREPARING SURFACE ANTIGEN PROTEINS FROM PROPAGATED INFLUENZA VIRUSES ON AN ANIMAL CELL CULTURE
MX2023011163A (en) Coronavirus vaccine formulations.
BR112022014830A2 (en) CORONA VIRUS VACCINE FORMULATIONS
WO2021189047A3 (en) Extracellular vesicles for therapy
WO2023094713A2 (en) Coronavirus vaccine
YU24004A (en) Interleukin-12 as a veterinary vaccine adjuvant
WO2023049636A3 (en) Cancer therapy compositions and uses thereof
RU2014127714A (en) TOXIN VACCINE Clostridium difficile
WO2023104114A3 (en) Rna formulations and lipids
MX2024006589A (en) CORONAVIRUS VACCINE FORMULATIONS.
MY207126A (en) 4/91 ibv vaccine with heterologous spike protein
US20240075128A1 (en) Immunogenic constructs, compositions, and methods for inducing immune response
US20190380961A1 (en) Multi-domain vesicle comprising immunosuppressive factor control material, production method therefor and immunomodulatory composition comprising same
WO2023053017A3 (en) Ionizable cationic compounds for messenger rna delivery
MX2023014468A (en) Virus-like particle vaccine for coronavirus.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021838378

Country of ref document: EP

Effective date: 20230210

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21838378

Country of ref document: EP

Kind code of ref document: A2